TKI | Targets | Incidence of all-grade HFSR (%) | Incidence of high-grade HFSR (%) |
Axitinib[1] | VEGFR-1, 2, and 3 | 29.2 | 9.6 |
Cabozantinib[2,3] | VEGFR-2, c-MET, RET, c-KIT, FLT3, Tie-2 | 35.3 | 9.5 |
Lenvatinib[4] | VEGFR-1, 2, and 3; FGFR-1, 2, 3, and 4; PDGFR-alpha; RET; KIT | 65.2 | 8.7 |
Pazopanib[5] | RAF, VEGFR-2 and 3, PDGFR-beta, c-KIT, FLT3, RET | 4.5 | 1.8 |
Regorafenib[6] | VEGFR-1, 2, and 3; Tie-2; FGFR-1; PDGFR-alpha and beta; c-KIT; RET; RAF; p38 MAPK | 60.5 | 20.4 |
Sorafenib[7] | VEGFR-2 and 3, PDGFR, A-RAF, B-RAF, C-RAF, FLT3 | 33.8 | 8.9 |
Sunitinib[8] | VEGFR-2, PDGFR, c-KIT, FLT3 | 18.9 | 5.5 |
Ripretinib[9] | KIT, PDGFR-alpha | 21.0 | 0 |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟